Physician profile
Whitfield Knapple
NPI 1912954504
$4,946.46
in general payments reported to CMS, 2019-2025
22 companies · $693 in 2025
The $693 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $359 · 2021: $740 · 2022: $734 · 2023: $733 · 2024: $1,051 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313 · Gift: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.16 |
| Gift | $163.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,353.26 | 2019-2025 | |
| Janssen Biotech, INC. | $473.78 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $334.15 | 2019-2022 | |
| Pfizer INC. | $316.96 | 2019-2024 | |
| Gilead Sciences, INC. | $298.96 | 2019-2023 | |
| Braintree Laboratories, INC. | $290.25 | 2019-2024 | Sutab, Suflave |
| Medtronic, INC. | $259.85 | 2024-2025 | Gi Genius, Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $191.72 | 2019-2024 | Entyvio |
| Novo Nordisk INC | $93.96 | 2025 | Wegovy |
| Celgene Corporation | $83.20 | 2022-2023 | Zeposia |
| Genzyme Corporation | $82.87 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $57.45 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $49.39 | 2019-2020 | |
| Allergan, INC. | $34.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $18.34 | 2024 | Dificid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $7.60 | 2025 | Voquezna |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitfield Knapple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.